Metoprolol Succinate Tablet, Film Coated, Extended Release
Product Images NDC 50090-5733

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Metoprolol Succinate (NDC 50090-5733). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500905733)

Label Image (Lbl500905733)
Metoprolol Succinate 25 mg extended-release film-coated tablets label from A-S Medication Solutions. The label indicates each tablet contains 23.75 mg Metoprolol Succinate USP equivalent to 25 mg of Metoprolol Tartrate. The product is supplied in a bottle with 30 tablets and storage instructions to keep at 77 degrees Fahrenheit. The label also shows the product NDC 50090-5733-0 and includes a QR code and barcode.*
FDA Label Image

Metoprolol-structure (Metoprolol Structure)

Metoprolol-structure (Metoprolol Structure)
Chemical structure of Metoprolol Succinate, showing the molecular arrangement including an aromatic ring, hydroxyl groups, amine groups, and carboxylic acid moieties consistent with the succinate salt form.*
FDA Label Image

Metoprolol-table1 (Metoprolol Table1)

Metoprolol-table1 (Metoprolol Table1)
A forest plot titled 'Results for Subgroups in MERIT-HE' showing relative risk and 95% confidence intervals for different subgroups across three outcomes: Total Mortality, Total Mortality or All-Cause Hospitalization (Time to First Event), and Total Mortality or Hospitalization for Heart Failure (Time to First Event). Subgroups include geographic regions, NYHA classes, ejection fraction levels, etiology, sex, race, previous MI, diabetes status, hypertension status, and heart rate categories. The plot compares TOPROL-XL and placebo effects with a horizontal axis ranging from 0 to 2 for relative risk.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.